Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (441-450 of 497) with videos related to

Pageof 50
Sort By:
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
The New England Journal of Medicine|March 28, 2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, Harry R Büller, Martin H Prins, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Journal of Neurology|February 15, 2020
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trialN Martinez-Majander, G Ntaios, Y Y Liu, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
The New England Journal of Medicine|June 25, 1981
Kawasaki syndrome: description of two outbreaks in the United StatesD M Bell, E W Brink, J L Nitzkin, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 22, 2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapySebastian F Ameriso, Pierre Amarenco, Lesly A Pearce, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50

Showing results (441-450 of 497) with videos related to

Sort By:
Pageof 50
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
The New England Journal of Medicine|March 28, 2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, Harry R Büller, Martin H Prins, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Journal of Neurology|February 15, 2020
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trialN Martinez-Majander, G Ntaios, Y Y Liu, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
The New England Journal of Medicine|June 25, 1981
Kawasaki syndrome: description of two outbreaks in the United StatesD M Bell, E W Brink, J L Nitzkin, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 22, 2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapySebastian F Ameriso, Pierre Amarenco, Lesly A Pearce, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50